OR WAIT null SECS
Juergen Popp, scientific director at the Leibniz Institute of Photonic Technology, is the recipient of the 2023 Federation of Analytical Chemistry and Spectroscopy Societies’ (FACCS) Charles Mann Award for Applied Raman Spectroscopy. Popp was presented with the award on October 10 at the SciX conference in Sparks, Nevada (1).
The Charles Mann Award recognizes an individual who has demonstrated advancements in the field of applied Raman Spectroscopy.
“Without exaggeration, it can be said that Raman spectroscopy has become one of the most important analytical methods, with applications in all fields of natural sciences, in medicine, but also in various other disciplines. Raman spectroscopy has even left the earth and flies to Mars,” Popp told Spectroscopy in an interview earlier this year (2).
Popp is a leading expert in biophotonic and optical health technology, from basic photonic research to translation into clinically applicable methods. He focuses specifically on the development and application of Raman techniques for biomedical diagnosis.
“Especially in the fields of life sciences and medicine, Raman-based technologies have demonstrated their great potential and increasingly complement established techniques such as fluorescence spectroscopy or microscopy,” Popp previously told Spectroscopy. “Raman spectroscopy enables label-free detection of the molecular composition as well as the morphology of complex samples such as biological cells or tissues with little or no sample preparation.”
Popp and his team have been studying methods for translating Raman approaches into routine clinical applications. During an award symposium at SciX, Popp spoke about applied Raman spectroscopy for clinical diagnosis and therapy to meet currently unmet medical needs. Popp presented research on instantaneous intraoperative histopathological diagnosis of tumors and the reliable on-site diagnosis and treatment of infectious diseases. The faster the tumor is detected a surgically removed using Raman spectroscopy surgical guidance, the higher the likelihood of recovery.
“Our research covers the entire range from fundamental research towards the development of new Raman spectroscopic instruments for clinical translational research,” he said. “Bridging this gap may be regarded as a token of quality of our work.”